Cushing's syndrome: an update on current pharmacotherapy and future directions (Q38541695)

4 September 2017

1 reference

title

Cushing's syndrome: an update on current pharmacotherapy and future directions (English)

1 reference

4 September 2017

0 references

1 reference

Sara G Creemers

1

1 reference

4 September 2017

Leo J Hofland

series ordinal

2

1 reference

4 September 2017

Steven W J Lamberts

series ordinal

3

1 reference

4 September 2017

Richard A Feelders

series ordinal

4

1 reference

4 September 2017

language of work or name

English

0 references

publication date

1 July 2015

1 reference

Expert Opinion on Pharmacotherapy

4 September 2017

1 reference

4 September 2017

16

1 reference

4 September 2017

12

1 reference

4 September 2017

1829-1844

1 reference

Neuropsychiatric disorders in Cushing's syndrome.

4 September 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Multisystem morbidity and mortality in Cushing's syndrome: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

The burden of Cushing's disease: clinical and health-related quality of life aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Outcome of Cushing's disease following transsphenoidal surgery in a single center over 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Mortality in patients treated for Cushing's disease is increased, compared with patients treated for nonfunctioning pituitary macroadenoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Long-term remission rates after pituitary surgery for Cushing's disease: the need for long-term surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Repeated transsphenoidal pituitary surgery (TS) via the endoscopic technique: a good therapeutic option for recurrent or persistent Cushing's disease (CD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Repeated transsphenoidal surgery to treat recurrent or residual pituitary adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Proton stereotactic radiotherapy for persistent adrenocorticotropin-producing adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Radiation therapy and stereotactic radiosurgery for the treatment of Cushing's disease: an evidence-based review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Favorable long-term outcomes of bilateral adrenalectomy in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Nelson's syndrome: a review of the clinical manifestations, pathophysiology, and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Bilateral adrenalectomy for refractory Cushing disease: a safe and definitive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

The ectopic adrenocorticotropin syndrome: clinical features, diagnosis, management, and long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Management of Cushing disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Cushing syndrome due to ectopic adrenocorticotropic hormone secretion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Genetics of Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

ACTH-independent macronodular adrenal hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

ARMC5 mutations in macronodular adrenal hyperplasia with Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

CT findings of primary pigmented nodular adrenocortical disease: rare cause of ACTH-independent Cushing syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Differential diagnosis and imaging in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Genetics and epigenetics of adrenocortical tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Adjuvant mitotane treatment for adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

New developments in the medical treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Octreotide exerts different effects in vivo and in vitro in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Dopamine receptor expression and function in corticotroph pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Dopamine agonists and the risk of cardiac-valve regurgitation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Valvular heart disease and the use of dopamine agonists for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing's disease--report of a case and literature review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Use of temozolomide in aggressive pituitary tumors: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Ketoconazole treatment in Cushing's syndrome: experience in 34 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Ketoconazole revisited: a preoperative or postoperative treatment in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Medical treatment of Cushing's syndrome: adrenal-blocking drugs and ketaconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Ketoconazole inhibits corticotropic cell function in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Use of ketoconazole in the treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Medical therapy of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Rationale for treatment and therapeutic options in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Adrenocortical carcinoma: a clinician's update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Mitotane alters mitochondrial respiratory chain activity by inducing cytochrome c oxidase defect in human adrenocortical cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Drugs in the medical treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Effects of mitotane treatment on human steroid metabolism: implications for patient management.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Clinical management of adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Merits and pitfalls of mifepristone in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing's disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Sustained improvements in plasma ACTH and clinical status in a patient with Nelson's syndrome treated with pasireotide LAR, a multireceptor somatostatin analog.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Effects of somatostatin analogs on glucose homeostasis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Cabergoline monotherapy in the long-term treatment of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Cabergoline therapy for Cushing disease throughout pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Treatment of Cushing's disease by O,p'DDD. Survey of 62 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Efficiency and tolerance of mitotane in Cushing's disease in 76 patients from a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

The use of the glucocorticoid receptor antagonist mifepristone in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

LCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Retinoic acid prevents experimental Cushing syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Potential role for retinoic acid in patients with Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Fluconazole inhibits human adrenocortical steroidogenesis in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Long term control of hypercortisolism with fluconazole: case report and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Stereoisomers of ketoconazole: preparation and biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Prolonged remission after long-term treatment with steroidogenesis inhibitors in Cushing's syndrome caused by ectopic ACTH secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Mifepristone effects on tumor somatostatin receptor expression in two patients with Cushing's syndrome due to ectopic adrenocorticotropin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Dopamine receptor expression and function in corticotroph ectopic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Cabergoline plus lanreotide for ectopic Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Propranolol Therapy for Ectopic β-Adrenergic Receptors in Adrenal Cushing's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Food-dependent Cushing's syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Adrenal cortical carcinoma--review of current knowledge and treatment practices

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Combination chemotherapy in advanced adrenocortical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

ACTH-independent macronodular adrenocortical hyperplasia reveals prevalent aberrant in vivo and in vitro responses to hormonal stimuli and coupling of arginine-vasopressin type 1a receptor to 11β-hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Cytotoxic activity of gemcitabine, alone or in combination with mitotane, in adrenocortical carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

ARMC5Mutations Are a Frequent Cause of Primary Macronodular Adrenal Hyperplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

Subclinical Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.1061995

10.1517/14656566.2015.1061995

21 January 2018

Identifiers

DOI

1 reference

release_xhid5z6amffrzlvde2r7d4ofs4

4 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xhid5z6amffrzlvde2r7d4ofs4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference